Comments

Regeneron Pharmaceuticals Analyst Ratings

REGNNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$703.26

-15.10-2.10%

At close: Dec 8, 4:00 PM EST

$703.26

N/A

After Hours: 6:03 PM EST

Overview News Earnings Options Dividends

Analyst Ratings

Insider Trades Short Interest Government Trades Stock Report

Consensus Rating¹

Buy

Highest Price Target¹

$1175.00

Lowest Price Target¹

$587.00

Consensus Price Target¹

$839.30

Regeneron Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:REGN | Benzinga

Regeneron Pharmaceuticals Inc has a consensus price target of $839.3 based on the ratings of 27 analysts. The high is $1175 issued by Evercore ISI Group on October 24, 2024. The low is $587 issued by Baird on April 30, 2025. The 3 most-recent analyst ratings were released by Canaccord Genuity, BMO Capital, and Morgan Stanley on December 4, 2025, December 4, 2025, and December 3, 2025, respectively. With an average price target of $891.33 between Canaccord Genuity, BMO Capital, and Morgan Stanley, there's an implied 26.74% upside for Regeneron Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast

Aug

Oct

Nov

Dec

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.2

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Analyst Firms Making Recommendations¹

Canaccord Genuity

BMO Capital

Morgan Stanley

Truist Securities

Scotiabank

¹calculated from analyst ratings

Analyst Ratings for Regeneron Pharmaceuticals

					Get Alert
Dec 4, 2025	50.3%	John NewmanCanaccord Genuity 48%	850 1.06K	Previous Buy Current Buy	Get Alert
Dec 4, 2025	20.87%	Evan David SeigermanBMO Capital 55%	725 850	Previous Outperform Current Outperform	Get Alert
Dec 3, 2025	9.06%	Matthew HarrisonMorgan Stanley 62%	767 767	Previous Overweight Current Equal-Weight	Get Alert
Nov 24, 2025	13.47%	Gregory RenzaTruist Securities 67%	798 812	Previous Current Buy	Get Alert
Nov 24, 2025	9.49%	Louise ChenScotiabank 60%	650 770	Previous Sector Perform Current Sector Perform	Get Alert
Nov 24, 2025	26.55%	Yifeng LiuHSBC 31%	890	Previous Initiates Current Buy	Get Alert
Nov 20, 2025	-0.46%	Mohit BansalWells Fargo 70%	615 700	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 7, 2025	-6.15%	Trung HuynhUBS 78%	595 660	Previous Neutral Current Neutral	Get Alert
Oct 29, 2025	-0.46%	Geoff MeachamCitigroup 72%	660 700	Previous Buy Current Buy	Get Alert
Oct 29, 2025	0.67%	Brian AbrahamsRBC Capital 56%	704 708	Previous Sector Perform Current Sector Perform	Get Alert
Oct 29, 2025	-12.55%	Mohit BansalWells Fargo 70%	580 615	Previous Equal-Weight Current Equal-Weight	Get Alert
Oct 29, 2025	5.22%	Carter GouldCantor Fitzgerald 64%	678 740	Previous Overweight Current Overweight	Get Alert
Oct 29, 2025	23%	Yatin SunejaGuggenheim 73%	815 865	Previous Buy Current Buy	Get Alert
Oct 29, 2025	-10.84%	Tim AndersonB of A Securities 63%	543 627	Previous Underperform Current Underperform	Get Alert
Oct 23, 2025	20.87%	John NewmanCanaccord Genuity 48%	850 850	Previous Buy Current Buy	Get Alert
Oct 14, 2025	20.87%	John NewmanCanaccord Genuity 48%	850 850	Previous Buy Current Buy	Get Alert
Oct 13, 2025	-6.15%	Geoff MeachamCitigroup 72%	650 660	Previous Buy Current Buy	Get Alert
Oct 10, 2025	7.5%	Matthew HarrisonMorgan Stanley 62%	756 761	Previous Overweight Current Overweight	Get Alert
Aug 27, 2025	11.05%	William PickeringBernstein 47%	753 781	Previous Outperform Current Outperform	Get Alert
Aug 27, 2025	18.16%	Akash TewariJefferies 49%	813 831	Previous Buy Current Buy	Get Alert
Aug 11, 2025	15.46%	Srikripa DevarakondaTruist Securities 65%	812 940	Previous Buy Current Buy	Get Alert
Aug 4, 2025	-9%	Evan David SeigermanBMO Capital 55%	600 640	Previous Outperform Current Outperform	Get Alert
Aug 4, 2025	8.21%	Matthew HarrisonMorgan Stanley 62%	754 761	Previous Overweight Current Overweight	Get Alert
Aug 4, 2025	-1.17%	Brian AbrahamsRBC Capital 56%	688 695	Previous Sector Perform Current Sector Perform	Get Alert
Aug 4, 2025	15.89%	Yatin SunejaGuggenheim 73%	810 815	Previous Buy Current Buy	Get Alert
Jul 23, 2025	20.87%	John NewmanCanaccord Genuity 48%	850 850	Previous Buy Current Buy	Get Alert
Jul 11, 2025	-16.96%	Trung HuynhUBS 78%	560 584	Previous Neutral Current Neutral	Get Alert
Jul 10, 2025	7.21%	Matthew HarrisonMorgan Stanley 62%	754 755	Previous Overweight Current Overweight	Get Alert
Jun 9, 2025	13.76%	Chris SchottJP Morgan 66%	800 950	Previous Overweight Current Overweight	Get Alert
Jun 5, 2025	-20.37%	Trung HuynhUBS 78%	560 633	Previous Neutral Current Neutral	Get Alert
Jun 2, 2025	-7.57%	Geoff MeachamCitigroup 72%	650 700	Previous Buy Current Buy	Get Alert
Jun 2, 2025	-14.68%	Evan David SeigermanBMO Capital 55%	600 800	Previous Outperform Current Outperform	Get Alert
Jun 2, 2025	7.36%	Matthew HarrisonMorgan Stanley 62%	755 958	Previous Overweight Current Overweight	Get Alert
May 30, 2025	-17.53%	Mohit BansalWells Fargo 70%	580 700	Previous Overweight Current Equal-Weight	Get Alert
May 27, 2025	34.09%	Brian AbrahamsRBC Capital 56%	943 943	Previous Outperform Current Outperform	Get Alert
May 14, 2025	-0.46%	Geoff MeachamCitigroup 72%	600 700	Previous Neutral Current Buy	Get Alert
May 5, 2025	36.22%	Matthew HarrisonMorgan Stanley 62%	958 1.08K	Previous Overweight Current Overweight	Get Alert
May 1, 2025	15.18%	Yatin SunejaGuggenheim 73%	810 940	Previous Buy Current Buy	Get Alert
Apr 30, 2025	35.09%	Chris SchottJP Morgan 66%	950 1K	Previous Overweight Current Overweight	Get Alert
Apr 30, 2025	33.66%	Srikripa DevarakondaTruist Securities 65%	940 975	Previous Buy Current Buy	Get Alert
Apr 30, 2025	14.32%	Salveen RichterGoldman Sachs 58%	804 917	Previous Buy Current Buy	Get Alert
Apr 30, 2025	34.09%	Brian AbrahamsRBC Capital 56%	943 1.05K	Previous Outperform Current Outperform	Get Alert
Apr 30, 2025	-0.46%	Mohit BansalWells Fargo 70%	700 750	Previous Overweight Current Overweight	Get Alert
Apr 30, 2025	13.76%	Evan David SeigermanBMO Capital 55%	800 865	Previous Outperform Current Outperform	Get Alert
Apr 30, 2025	-9.99%	Trung HuynhUBS 78%	633 768	Previous Neutral Current Neutral	Get Alert
Apr 30, 2025	-16.53%	Brian SkorneyBaird 60%	587 652	Previous Neutral Current Neutral	Get Alert
Apr 29, 2025	27.98%	Hartaj SinghOppenheimer 48%	900 925	Previous Outperform Current Outperform	Get Alert
Apr 25, 2025	-7.29%	Brian SkorneyBaird 60%	652 759	Previous Neutral Current Neutral	Get Alert
Apr 23, 2025	38.64%	Srikripa DevarakondaTruist Securities 65%	975 1K	Previous Buy Current Buy	Get Alert
Apr 22, 2025	20.87%	John NewmanCanaccord Genuity 48%	850 1.15K	Previous Buy Current Buy	Get Alert
Apr 22, 2025	-1.17%	Carter GouldCantor Fitzgerald 64%	695	Previous Current Overweight	Get Alert
Apr 17, 2025	-22.22%	Tim AndersonB of A Securities 63%	547 575	Previous Underperform Current Underperform	Get Alert
Apr 14, 2025	30.39%	Salveen RichterGoldman Sachs 58%	917 1.02K	Previous Buy Current Buy	Get Alert
Apr 9, 2025	53.71%	Matthew HarrisonMorgan Stanley 62%	1.08K 1.15K	Previous Overweight Current Overweight	Get Alert
Apr 3, 2025	31.53%	Hartaj SinghOppenheimer 48%	925 950	Previous Outperform Current Outperform	Get Alert
Mar 31, 2025	42.19%	Chris SchottJP Morgan 66%	1K 1.1K	Previous Overweight Current Overweight	Get Alert
Feb 5, 2025	7.93%	Brian SkorneyBaird 60%	759 940	Previous Neutral Current Neutral	Get Alert
Feb 5, 2025	18.59%	David RisingerLeerink Partners 72%	762 834	Previous Market Perform Current Outperform	Get Alert
Jan 28, 2025	8.35%	Andrew BerensLeerink Partners 52%	762 880	Previous Market Perform Current Market Perform	Get Alert
Jan 28, 2025	6.65%	Geoff MeachamCitigroup 72%	750 795	Previous Neutral Current Neutral	Get Alert
Jan 27, 2025	44.04%	Christopher RaymondPiper Sandler 55%	1.01K 1.2K	Previous Overweight Current Overweight	Get Alert
Jan 16, 2025	4.94%	Trung HuynhUBS 78%	738 1.13K	Previous Buy Current Neutral	Get Alert
Jan 14, 2025	13.04%	Geoff MeachamCitigroup 72%	795 895	Previous Neutral Current Neutral	Get Alert
Jan 10, 2025	35.09%	Hartaj SinghOppenheimer 48%	950 1K	Previous Outperform Current Outperform	Get Alert
Jan 10, 2025	27.98%	Mohit BansalWells Fargo 70%	900 1.05K	Previous Overweight Current Overweight	Get Alert
Jan 8, 2025	42.76%	Srikripa DevarakondaTruist Securities 65%	1K 1.13K	Previous Buy Current Buy	Get Alert
Jan 7, 2025	52.15%	William PickeringBernstein 47%	1.07K 1.11K	Previous Outperform Current Outperform	Get Alert
Dec 10, 2024	-19.66%	Tim AndersonB of A Securities 63%	565	Previous Current Underperform	Get Alert
Nov 15, 2024	63.52%	Alexandria HammondWolfe Research 62%	1.15K	Previous Initiates Current Outperform	Get Alert
Nov 14, 2024	27.26%	Geoff MeachamCitigroup 72%	895	Previous Initiates Current Neutral	Get Alert
Nov 6, 2024	42.19%	Hartaj SinghOppenheimer 48%	1K 1.15K	Previous Outperform Current Outperform	Get Alert
Nov 1, 2024	25.13%	David RisingerLeerink Partners 72%	880 1.08K	Previous Market Perform Current Market Perform	Get Alert
Nov 1, 2024	68.36%	Matthew HarrisonMorgan Stanley 62%	1.18K 1.24K	Previous Overweight Current Overweight	Get Alert
Nov 1, 2024	72.77%	Brian AbrahamsRBC Capital 56%	1.22K 1.26K	Previous Outperform Current Outperform	Get Alert
Nov 1, 2024	51.44%	Carter GouldBarclays 64%	1.07K 1.08K	Previous Overweight Current Overweight	Get Alert
Nov 1, 2024	69.92%	Christopher RaymondPiper Sandler 55%	1.2K 1.24K	Previous Overweight Current Overweight	Get Alert
Nov 1, 2024	69.21%	Evan David SeigermanBMO Capital 55%	1.19K 1.3K	Previous Outperform Current Outperform	Get Alert
Nov 1, 2024	60.11%	Srikripa DevarakondaTruist Securities 65%	1.13K 1.14K	Previous Buy Current Buy	Get Alert
Oct 25, 2024	79.17%	Brian AbrahamsRBC Capital 56%	1.26K 1.26K	Previous Outperform Current Outperform	Get Alert
Oct 24, 2024	67.08%	Cory KasimovEvercore ISI Group 68%	1.18K 1.25K	Previous Outperform Current Outperform	Get Alert
Oct 24, 2024	63.52%	Chris SchottJP Morgan 66%	1.15K 1.2K	Previous Overweight Current Overweight	Get Alert
Oct 23, 2024	44.33%	Olivia BrayerCantor Fitzgerald 57%	1.01K 1.01K	Previous Neutral Current Neutral	Get Alert
Oct 23, 2024	53.57%	Carter GouldBarclays 64%	1.08K 1.22K	Previous Overweight Current Overweight	Get Alert
Oct 22, 2024	49.3%	Mohit BansalWells Fargo 70%	1.05K 1.2K	Previous Overweight Current Overweight	Get Alert
Oct 22, 2024	79.17%	Brian AbrahamsRBC Capital 56%	1.26K 1.26K	Previous Outperform Current Outperform	Get Alert
Oct 16, 2024	61.68%	Srikripa DevarakondaTruist Securities 65%	1.14K 1.2K	Previous Buy Current Buy	Get Alert
Oct 4, 2024	79.17%	Brian AbrahamsRBC Capital 56%	1.25K 1.26K	Previous Outperform Current Outperform	Get Alert
Sep 24, 2024	78.03%	Brian AbrahamsRBC Capital 56%	1.25K 1.28K	Previous Outperform Current Outperform	Get Alert
Sep 24, 2024	84.85%	Evan David SeigermanBMO Capital 55%	1.3K 1.3K	Previous Outperform Current Outperform	Get Alert
Sep 24, 2024	70.63%	Srikripa DevarakondaTruist Securities 65%	1.2K 1.2K	Previous Buy Current Buy	Get Alert
Sep 24, 2024	53.14%	David RisingerLeerink Partners 72%	1.08K 1.18K	Previous Outperform Current Market Perform	Get Alert
Sep 23, 2024	70.63%	Mohit BansalWells Fargo 70%	1.2K 1.2K	Previous Overweight Current Overweight	Get Alert
Sep 17, 2024	82.29%	Brian AbrahamsRBC Capital 56%	1.28K 1.28K	Previous Outperform Current Outperform	Get Alert
Sep 16, 2024	44.33%	Olivia BrayerCantor Fitzgerald 57%	1.01K 1.01K	Previous Neutral Current Neutral	Get Alert
Sep 9, 2024	44.33%	Olivia BrayerCantor Fitzgerald 57%	1.01K 1.01K	Previous Neutral Current Neutral	Get Alert
Sep 9, 2024	82.29%	Brian AbrahamsRBC Capital 56%	1.25K 1.28K	Previous Outperform Current Outperform	Get Alert
Sep 5, 2024	77.74%	Brian AbrahamsRBC Capital 56%	1.25K 1.25K	Previous Outperform Current Outperform	Get Alert
Aug 23, 2024	76.61%	Christopher RaymondPiper Sandler 55%	1.17K 1.24K	Previous Overweight Current Overweight	Get Alert
Aug 2, 2024	70.63%	Chris SchottJP Morgan 66%	1.15K 1.2K	Previous Overweight Current Overweight	Get Alert
Aug 2, 2024	76.32%	Brian AbrahamsRBC Capital 56%	1.23K 1.24K	Previous Outperform Current Outperform	Get Alert

FAQ

What is the target price for Regeneron Pharmaceuticals (REGN) stock?

The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by Canaccord Genuity on December 4, 2025. The analyst firm set a price target for $1057.00 expecting REGN to rise to within 12 months (a possible 50.30% upside). 68 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Regeneron Pharmaceuticals (REGN)?

The latest analyst rating for Regeneron Pharmaceuticals (NASDAQ:REGN) was provided by Canaccord Genuity, and Regeneron Pharmaceuticals maintained their buy rating.

When was the last upgrade for Regeneron Pharmaceuticals (REGN)?

The last upgrade for Regeneron Pharmaceuticals Inc happened on May 14, 2025 when Citigroup raised their price target to $700. Citigroup previously had a neutral for Regeneron Pharmaceuticals Inc.

When was the last downgrade for Regeneron Pharmaceuticals (REGN)?

The last downgrade for Regeneron Pharmaceuticals Inc happened on December 3, 2025 when Morgan Stanley changed their price target from $767 to $767 for Regeneron Pharmaceuticals Inc.

When is the next analyst rating going to be posted or updated for Regeneron Pharmaceuticals (REGN)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regeneron Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regeneron Pharmaceuticals was filed on December 4, 2025 so you should expect the next rating to be made available sometime around December 4, 2026.

Is the Analyst Rating Regeneron Pharmaceuticals (REGN) correct?

While ratings are subjective and will change, the latest Regeneron Pharmaceuticals (REGN) rating was a maintained with a price target of $850.00 to $1057.00. The current price Regeneron Pharmaceuticals (REGN) is trading at is $703.26, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.